Emgality for Migraine in Breastmilk
NCT06085144
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who were or were not breastfed after maternal treatment. In this prospective observational study, the study team proposes to prospectively collect serial milk samples from 30 adult women who are treated with galcanezumab for migraine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Migraine
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 45 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, San Francisco
- Last updated on ClinicalTrials.gov
- August 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Francisco · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.